Patents Assigned to SmithKline Beecham Corp.
-
Patent number: 7666857Abstract: An improved thrombopoietin mimetic, the choline salt of 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3?-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one.Type: GrantFiled: October 21, 2004Date of Patent: February 23, 2010Assignee: SmithKline Beecham Corp.Inventors: Christopher S. Brook, Li-Jen J. Ping
-
Patent number: 7662804Abstract: Disclosed herein are novel diazenyl pyrazole compounds and related compounds. Also disclosed herein are methods of using these compounds for the treatment of diseases and conditions associated with modulating a thrombopoietin activity.Type: GrantFiled: November 21, 2006Date of Patent: February 16, 2010Assignee: SmithKline Beecham Corp.Inventors: Lin Zhi, E. Adam Kallel, Dean P. Phillips
-
Patent number: 7648971Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Type: GrantFiled: June 18, 2008Date of Patent: January 19, 2010Assignee: SmithKline Beecham Corp.Inventors: Kevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan I. Luengo, Sophie Visonneau
-
Patent number: 7645771Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).Type: GrantFiled: December 12, 2003Date of Patent: January 12, 2010Assignee: SmithKline Beecham Corp.Inventors: Wieslaw Mieczyslaw Kazmierski, Chrisopher Joseph Aquino, Neil Bifulco, Eric Eugene Boros, Brian Andrew Chauder, Pek Yoke Chong, Maosheng Duan, Felix Deanda, Jr., Cecilia Suarez Koble, Ed Williams McLean, Jennifer Poole Peckham, Angilique C Perkins, James Benjamin Thompson, Dana Vanderwall
-
Patent number: 7625890Abstract: Invented are novel 1H-imidazo[4,5-c]pyridin-2-yl compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.Type: GrantFiled: June 27, 2007Date of Patent: December 1, 2009Assignee: SmithKline Beecham Corp.Inventors: Dirk A. Heerding, Tammy J. Clark, Jack Dale Leber, Igor Safonov
-
Patent number: 7608621Abstract: The invention described herein relates to certain pyridazinedione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.Type: GrantFiled: January 11, 2008Date of Patent: October 27, 2009Assignee: SmithKline Beecham, Corp.Inventors: Antony N. Shaw, Kevin J. Duffy, William Henry Miller, Andrea K. Myers, Michael N. Zimmerman
-
Patent number: 7547719Abstract: An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid.Type: GrantFiled: May 21, 2003Date of Patent: June 16, 2009Assignee: SmithKline Beecham Corp.Inventor: Stephen Moore
-
Publication number: 20090131319Abstract: The present invention relates to novel members of the Tumor Necrosis Factor family of receptors. The invention provides isolated nucleic acid molecules encoding a human TR2 receptor and two splice variants thereof. TR2 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR2 receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of TR2 receptors. Further provided are therapeutic methods for treating disease states related to aberrant proliferation and differentiation of cells which express the TR2 receptors.Type: ApplicationFiled: September 23, 2008Publication date: May 21, 2009Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Jian Ni, Craig A. Rosen, Reiner L. Gentz, Sally Doreen Patricia Lyn, Mark Robert Hurle
-
Patent number: 7514437Abstract: A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a mammal in need thereof of an effective amount of a compound of the formula (I) and/or a physiologically acceptable derivative thereof, wherein the substituents have the meaning given in the description. Disclosed are also novel compounds of formula (I) and processes for their preparation.Type: GrantFiled: December 20, 2002Date of Patent: April 7, 2009Assignee: SmithKline Beecham Corp.Inventors: Alan David Borthwick, Richard Jonathan Hatley, Deirdre Mary Bernadette Hickey, John Liddle, David George Hubert Livermore, Andrew McMurtrie Mason, Neil Derek Miller, Fabrizio Nerozzi, Steven Leslie Sollis, Anna Katrin Szardenings, Paul Graham Wyatt
-
Patent number: 7514473Abstract: Novel Calcilytic compounds and methods of using them are provided.Type: GrantFiled: November 25, 2003Date of Patent: April 7, 2009Assignee: SmithKline Beecham, Corp.Inventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
-
Patent number: 7491728Abstract: The pyrimidinone compounds are disclosed. Methods of preparing the pyrimidinone compounds are also disclosed.Type: GrantFiled: April 7, 2004Date of Patent: February 17, 2009Assignee: SmithKline Beecham Corp.Inventors: Irina V. Shcherbakova, Manuel F. Balanddrin, Guangfei Huang, Otto Geoffroy, John Fox, Robert Marquis, Dennis Shinji Yamashita, Juan Luengo, Wenyong Wang
-
Patent number: 7473686Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Type: GrantFiled: January 8, 2007Date of Patent: January 6, 2009Assignee: SmithKline Beecham Corp.Inventors: Kevin J. Duffy, Connie Erickson-Miller, Julian Jenkins, Juan I. Luengo, Sophie Visonneau
-
Publication number: 20080317754Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.Type: ApplicationFiled: June 1, 2007Publication date: December 25, 2008Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Gregg A. Hastings, Mark D. Adams, Claire M. Fraser, Norman H. Lee, Ewen F. Kirkness, Judith A. Blake, Lisa M. Fitzgerald, Fred H. Drake, Maxine Gowan
-
Publication number: 20080318835Abstract: ITGL-TSP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ITGL-TSP polypeptides and polynucleotides in the design of protocols for the treatment of, angiogenic diseases (cancer, cancer metastasis, chronic inflammatory disorders, rheumatoid arthritis, atherosclerosis, macular degeneration, diabetic retmopathy), restenosis, Alzheimer's, disease and tissue remodeling, among others, and diagnostic assays for such conditions.Type: ApplicationFiled: February 29, 2008Publication date: December 25, 2008Applicants: Human Genome Sciences, Inc., SmithKline Beecham Corp.Inventors: Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett, Gregg A. Hastings
-
Publication number: 20080312146Abstract: The present invention relates to novel anti-angiogenic proteins, related to thrombospondin. More specifically, isolated nucleic acid molecules are provided encoding human METH1 and METH2. METH1 and METH2 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for the prognosis of cancer and therapeutic methods for treating individuals in need of an increased amount of METH1 or METH2. Also provided are methods for inhibiting angiogenesis using METH1 or METH2.Type: ApplicationFiled: May 21, 2007Publication date: December 18, 2008Applicants: Human Genome Sciences, Inc., Beth Israel Deaconess Medical Center, SmithKline Beecham Corp.Inventors: Luisa Iruela-Arispe, Gregg A. Hastings, Steven M. Ruben, Zdenka L. Jonak, Stephen H. Trulli, James A. Fornwald, Jonathan A. Terrett
-
Patent number: 7456211Abstract: The present invention involves novel anti-bacterial compounds represented by Formula (I), pharmaceutical compositions thereof, their use as PDF inhibitors, and their use in the treatment of bacterial infections.Type: GrantFiled: March 7, 2007Date of Patent: November 25, 2008Assignee: SmithKline Beecham CorpInventors: Kelly M. Aubart, Jia-Ning Xiang, Siegfried B. Christensen, IV, Xiangmin Liao, Maxwell D. Cummings
-
Patent number: 7452874Abstract: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.Type: GrantFiled: January 8, 2007Date of Patent: November 18, 2008Assignee: SmithKline Beecham Corp.Inventors: Kevin J. Duffy, Juan I. Luengo, Antony N. Shaw, Kenneth Wiggall
-
Patent number: 7419988Abstract: The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.Type: GrantFiled: August 8, 2007Date of Patent: September 2, 2008Assignee: SmithKline Beecham CorpInventors: Dashyant Dhanak, Kenneth Allen Newlander
-
Patent number: 7332485Abstract: Novel PDF inhibitors and novel methods for their use are provided.Type: GrantFiled: July 8, 2004Date of Patent: February 19, 2008Assignee: SmithKline Beecham CorpInventors: Kelly M. Aubart, Siegfried Benjamin Christensen, IV, Chaya Duraiswami, Joseph M. Karpinski
-
Patent number: D609095Type: GrantFiled: September 9, 2008Date of Patent: February 2, 2010Assignee: SmithKline Beecham Corp.Inventors: William J. Kooser, Mark R. Prus